Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma—a Pediatric Brain Tumor Consortium study

A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in cases of pediatric recurrent ependymoma (EPN) to estimate sustained objective response rate and progression-free survival (PFS). Eligible patients received 2 doses of single-agent BVZ intravenously (10 mg/kg) 2 weeks apa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Gururangan, Sridharan, Fangusaro, Jason, Young Poussaint, Tina, Onar-Thomas, Arzu, Gilbertson, Richard J., Vajapeyam, Sridhar, Gajjar, Amar, Goldman, Stewart, Friedman, Henry S., Packer, Roger J., Boyett, James M., Kun, Larry E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2012
Pynciau:
Clinical Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3480265/
https://ncbi.nlm.nih.gov/pubmed/23019233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos213
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg